

## LIST OF PUBLICATIONS

Ray P., Wright J., Adam J., Bennett J., **Boucharens S.**, Black D., Cook A., Brown A.R., Epemolu O., Fletcher D., Haunso A., Huggett M., Jones P., Laats S., Lyons A., Mestres J., de Man J., Morphy R., Rankovic Z., Sherborne B., Sherry L., van Straten N., Westwood P., Zaman G. (2011). Fragment-based discovery of 6-substituted isoquinalin-1-amine based ROCK-1 inhibitors. *Bioorg. Med. Chem. Lett.* 21 (1): 97-101.

Ray P., Wright J., Adam J., **Boucharens S.**, Black D., Brown A.R., Epemolu O., Fletcher D., Huggett M., Jones P., Laats S., Lyons A., de Man J., Morphy R., Sherborne B., Sherry L., van Straten N., Westwood P., York M. (2011). Optimisation of 6-substituted isoquinolin-1-amine based ROCK-1 inhibitors. *Bioorg. Med. Chem. Lett.* December 28.

**Boucharens S.**, (2010) Outsourcing Compound Inventory: Trend or real Benefits. *Pharmaceutical Outsourcing* November/December 2010.

Cai J., Baugh M., Black d., Long C., Bennett J., Dempster M., Fradera X., Gillespie J., Andrews A., **Boucharens S.**, Bruin J., Cameron K., Cumming I., Hamilton W., Jones P., Kaptein A., Kinghorn E., Maidment M., Martin I., Mitchell A., Rankovic Z., Robinson J., Scullion P., Uitdehaag J., Vink P., Westwood P., van Zeeland M., van Berkomp L., Bastiani M., Meulemans T., (2010). 6-Phenyl-1H-imidazo[4,5-c]pyridine-4-carbonitrile as cathepsin S inhibitors. *Bioorg. Med. Chem. Lett.* 20 (15): 4350-4354.

Cai J., Bennett J., Rankovic R., Dempster M., Fradera X., Gillespie J., Cumming I., Finlay W., Baugh M., **Boucharens S.**, Bruin J., Cameron K., Hamilton W., Kerr J., Kinghorn E., McGarry G., Robinson J., Scullion P., Uitdehaag J., van Zeeland M., Potin D., Saniere L., Fouquet A., Chevallier F., Deronzier H., Dorleans C., Nicolai E., (2010). 2-Phenyl-9H-purine-6-carbonitrile derivatives as selective cathepsin S inhibitors. *Bioorg. Med. Chem. Lett.* 20 (15): 4447-4450.

Rankovic Z., Cai J., Fradera X., Dempster M., Mistry A., Mitchell A., Long C., Hamilton E., King A., **Boucharens S.**, Jamieson C., Gillespie J., Cumming I., Uidehaag J., Zeeland M.V., (2010). Dioxotriazines as a novel series of Cathepsin K inhibitors. *Bioorg. Med. Chem. Lett.* 20 (5): 1488-1490.

Subbra G., Amblard M., Verdie P., **Komesli S.**, Dutartre P., Renaut P. and Martinez J., (2007). Synthesis and TGF- $\beta$  Receptor Binding Inhibition of Multibranched Compounds. *QSAR & Combi Sci.* 26 (4): 496-510.

Durand P., Peralba P., Derain V., **Komesli S.** and Renaut P., (2001) Asymmetric total synthesis of natural Diheteropeptin. *Tetrahedron Letters.* 42 (11): 2121-2124.

Docagne F., Colloc'h N., Bougueret V., Page M., Paput J., Tripier M., Dutartre P., MacKenzie E. T., Buisson A., **Komesli S.** and Vivien D., (2001). A soluble transforming growth factor- $\beta$  (TGF- $\beta$ ) type I receptor mimics TGF- $\beta$  responses. *J. Biol. Chem.*, 276 (49): 46243-46250.

Ruocco A., Nicole O., Docagne F., Ali C., Chazaviel L., **Komesli S.**, Yablonsky F., Roussel S., MacKenzie E. T., Vivien D. and Buisson A., (1999). A transforming growth factor-beta antagonist unmasks the neuroprotective role of this endogenous cytokine in excitotoxic and ischemic brain injury. *J. of Cereb. Blood Flow Metab.*, 19 (12) : 1345-1353.

**Komesli S.**, Dumas C., and Dutartre P., (1999). Interaction of the immunosuppressant LF08-0299 (Tresperimus) with Hsc70 constitutive heat shock proteins : occurs but immunosuppression activity is not mediated directly by this binding. *Int. J. Immunopharmac.*, 21 : 349-358.

**Komesli S.**, Vivien D. and Dutartre P., (1998). Chimeric extracellular domain of type II transforming growth factor (TGF)- $\beta$  receptor fused to the Fc region of human immunoglobulin as a TGF- $\beta$  antagonist. *Eur. J. Bioch.*, 254 : 505-513.

Chevrier V., **Komesli S.**, Vantard M., Schmit A. C., Lambert A. M., and Job D., (1992). A monoclonal antibody raised against mammalian centrosomes and screened by recognition of plant microtubules

organizing centers, identifies a pericentriolar component in different cell types. *J. Cell Science*, 101 : 823-835.

Tournier F., **Komesli S.**, Paintrand M., Job D., and Bornens M., (1991). The intercentriolar linkage is critical for the ability of heterologous centrosomes to induce parthenogenesis in Xenopus. *J. Cell Biol.*, 113 : 1361-1369.

**Komesli S.**, (1991). Structure et fonctions des centrosomes isolés à partir de thymocytes de veau. Nouvelle thèse de **Doctorat de l'université** J. Fourier, Grenoble.

**Komesli S.**, Tournier F., Paintrand M., Job D., and Bornens M., (1989). Mass isolation of calf thymus centrosomes : the identification of a specific configuration. *J. Cell Biol.*, 109 : 2869-2878.

## BOOK CHAPTER

**Boucharens S.**, Warner A., (2010) Outsourcing Sample Management. *Management of Chemical and Biological samples for screening application. Wigglesworth M. and Wood T. Editions* (submitted).

## TECHNICAL REVUES

**Komesli S.**, Page M. and Dutartre P., (1999) Use of FlashPlate Technology for in vitro measurement of <sup>125</sup>I-Labeled TGF-β1 binding on chimeric extracellular domain of type II transforming growth factor receptor. NEN® Life Science Products. FlashPlate® File #14

## ORAL PRESENTATIONS

**Boucharens S.**, (2010). Saving Money and Time by implementing Compound Management Outsourcing Strategies. Webinar . <http://www.pharma-ig.com/webinarinfo.cfm?externalid=234> **October 27, 2010.**

**Boucharens S.**, (2010). Implementing Outsourcing Strategies: Economic and Organizational Advantages of Outsourcing. IQPC - Pharma IQ's - **Compound Management and Integrity. Philadelphia 2010**

**Boucharens S.**, (2010). Getting more out of your REMP Store: Challenges of 1536 format and acoustic dispenser compounds supplies. **Sample Management Club. Tokyo 2010**

**Boucharens S.**, (2010). Outsourcing Compound Inventory Case Study. IQPC - Pharma IQ's - **Compound Management and Integrity. London 2010**

**Komesli S.**, (2009). Schering-Plough-Organon Case Study: Integration of Compound Libraries Post Merger. IQPC - Pharma IQ's - **Compound Management and Integrity. London 2009**

**Komesli S.**, (2008). hERG, a cardiac Safety Assay Case Study: Leveraging Organon's new IT infrastructure to standardize assays, track compounds and improve the overall quality process and workflows from store – site – screen. IQPC - Pharma IQ's - **Compound Management and Integrity. London 2008**

**Komesli S.**, (2007). Organon's New Automation Platform and IT Environment. IQPC - Pharma IQ's – **Strategies for Enhancing Drug Discovery Automation. Amsterdam 2007**

**Komesli S.**, (2007). The impact of quality improvements on HTS and Pharmacology: Organon case study. IQPC - Pharma IQ's - **Compound Management, Integrity and Quality Control. London 2007**

**Komesli S.**, (2006). HTS has become a fundamental element in the Drug Discovery process as part of the continuing quest for high quality hits and leads. ELRIG Meeting – **Chemical & Biological Sample Management.**